TABLE 3.
Clinical characteristics of JAK2V617F positive ET patients from University of Florence cohort stratified by their variant allele frequency (VAF, ≤ 35% vs. > 35%)
| Clinical and laboratory variables | All JAK2 patients (n = 471) | JAK2 V617F VAF ≤35% (n = 364; 77.3%) | JAK2 V617F VAF > 35% (n = 107; 22.7%) | p valuesa |
|---|---|---|---|---|
| Age in year; median (range) | 62.0 (14.9–92.9) | 60.1 (14.9–92.9) | 66.5 (17.5–85.3) | 0.02 |
| Age ≥ 60 years; n (%) | 253 (53.7) | 183 (50.3) | 70 (65.4) | 0.01 |
| Sex females; n (%) | 318 (67.5) | 258 (70.9) | 60 (56.1) | 0.008 |
|
White blood cells × 109/L; median (range) N evaluable = 458 |
8.7 (3.7–18.2) | 8.6 (4.0–18.2) | 9.2 (3.7–18.2) | 0.1 |
|
White blood cells ≥11 × 109/L; n (%) N evaluable = 458 |
90 (19.6) | 67 (18.9) | 23 (22.3) | 0.3 |
| Hemoglobin, g/dl; median (range) | 14.2 (11.8–16.5) | 14.2 (11.8–16.5) | 14.6 (11.8–16.5) | 0.02 |
|
Hematocrit, % median (range) |
43.8 (36.0–50.0) | 43.4 (36.0–50.0) | 45 (37.0–50.0) | 0.003 |
| Platelets × 109/L; median (range) | 698 (455–1881) | 694 (455–1867) | 728 (455–1881) | 0.03 |
| Platelets ≥1000 × 109/L; n (%) | 61 (12.9) | 43 (11.8) | 18 (16.8) | 0.3 |
| Palpable splenomegaly; n (%) | 67 (14.2) | 40 (11.0) | 27 (25.2) | 0.0003 |
| Constitutional symptoms; n (%) | 27 (5.7) | 15 (4.1) | 12 (11.2) | 0.009 |
|
Major thrombosis before diagnosis; n (%) N evaluable = 405 |
35 (8.6) | 25 (8.0) | 10 (11.0) |
0.4 |
|
Major thrombosis at diagnosis; n (%) N evaluable = 397 |
31 (7.8) | 21 (6.8) | 10 (11.2) | 0.09 |
|
Overall thrombosis at follow‐up; n (%) N evaluable = 470 |
69 (14.7) | 52 (14.3) | 17 (15.9) | 0.7 |
|
Overall major bleeding; n (%) N evaluable = 470 |
41 (8.7) | 34 (9.4) | 7 (6.5) | 0.4 |
|
Overall minor bleeding; n (%) N evaluable = 467 |
54 (11.6) | 40 (11.1) | 14 (13.1) | 0.6 |
|
Cardiovascular risk factors; n (%) N evaluable = 395 |
235 (59.5) | 186 (60.0) | 49 (57.6) | 0.7 |
|
Microcirculatory symptoms; n (%) N evaluable = 466 |
149 (32.0) | 113 (31.4) | 36 (34.0) | 0.6 |
| MF progression; n (%) | 23 (4.9) | 7 (1.9) | 16 (14.9) | <0.001 |
| AML progression: n (%) | 9 (1.9) | 5 (1.4) | 4 (3.7) | 0.1 |
| Death; n (%) | 77 (16.3) | 51 (13.9) | 28 (25.9) | 0.003 |
Abbreviations: VAF, variant allele frequency.
Significant p values are highlighted in bold.